Damian Sendrowski

Dr. Damian Sendrowski

Institute of Health Sciences, Pomeranian University in Słupsk, Słupsk, Poland
orcid
Academic Assistant and Lecturer.

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
Damian SendrowskiDamian Sendrowski
Damian Sendrowski
APAgata Polańska-Szczap
Agata Polańska-Szczap
BHBeata Hus
Beata Hus
AVAnastasiia Vlaieva
Anastasiia Vlaieva
SMSzymon Markowski
Szymon Markowski
DKDariusz Kozlowski
Dariusz Kozlowski
Background: Peripheral muscle electrostimulation (PME), encompassing neuromuscular electrical stimulation (NMES) and functional electrical stimulation (FES), has been increasingly acknowledged as an effective adjunctive or complementary treatment to voluntary exercise in elderly cardiac patients who cannot perform sufficient amounts of exercise, for whom there is limited research on optimal protocols. Sarcopenia, defined as a progressive decrease in muscle mass, strength and function, affects approximately 34% of heart failure (HF) patients and considerably worsens their prognosis. The objective of this systematic review is to summarize current evidence on the theoretical mechanisms, physiological pathways, safety and efficacy of PME in older adults within a cardiac rehabilitation (CR) setting, with a specific emphasis on sarcopenia reversal. Methods: We performed a systematic review following the PRISMA 2020 guidelines. A systematic search was conducted on the PubMed, Embase, Cochrane Library, CINAHL and PEDro databases from inception until December 2025. We searched for randomized controlled trials (RCTs) and controlled clinical trials focusing on PME in patients with cardiac diseases aged 65 years or older. The main outcomes were physical function (assessed with the Short Physical Performance Battery [SPPB] and 6 min walk distance [6MWD]), muscle strength, muscle mass and safety. The Cochrane Risk of Bias tool was used to evaluate the quality of the studies. Results: Eight studies were included, with 387 participants and a mean age between 78 and 85 years. PME consistently improved lower-extremity muscle strength (MD: 5.2% body weight, 95% CI = 1.2–9.1, p = 0.013) along with SPPB scores, which ranged from +2.3 to +2.67 points (all p < 0.05). Home-based PME (NMES) achieved 100% adherence rates, and no cardiovascular adverse events were reported. The mechanisms by which PME is beneficial involve peripheral skeletal muscle adaptations without eliciting central hemodynamic stress, increased endothelial function, aerobic enzyme activity, protein anabolism stimulation or muscle proteolysis inhibition. No significant effects were observed on BNP levels, hospital readmissions or mortality. PME has been shown to attenuate the progression of sarcopenia through hypertrophy of type I and II muscle fibers, as well as mitochondrial biogenesis. Conclusions: PME is a safe, feasible adjunct to conventional CR in frail, elderly cardiac patients, particularly those with exercise intolerance and sarcopenia. It improves peripheral muscle function, physical performance, and muscle protein balance without cardiovascular stress. Larger multicenter trials are needed to establish optimal protocols and long-term clinical outcomes.

8 July 2026 in Frontiers in Cardiovascular Medicine
Verified
Journal Article
Open access
PDF file
Damian SendrowskiDamian Sendrowski
Damian Sendrowski
APAgata Polańska-Szczap
Agata Polańska-Szczap
BHBeata Hus
Beata Hus
AVAnastasiia Vlaieva
Anastasiia Vlaieva
SMSzymon Markowski
Szymon Markowski
DKDariusz Kozłowski
Dariusz Kozłowski
Background: Whole-body electrical muscle stimulation (WB-EMS) is an emerging modality that simultaneously activates multiple large muscle groups via a wearable electrode suit. Although localized neuromuscular electrical stimulation (NMES) has demonstrated efficacy as an adjunctive strategy in cardiac rehabilitation (CR), WB-EMS has not previously been investigated in patients with heart failure and reduced ejection fraction (HFrEF) undergoing CR. Case description: A 73-year-old male with recurrent non-ST-elevation myocardial infarction (NSTEMI), chronic heart failure (LVEF 20%–25%), and New York Heart Association class III was admitted for a 24-day inpatient CR programme. Standard CR (cycle ergometry, treadmill, resistance exercises, respiratory physiotherapy, and education, five days/week) was augmented with WB-EMS (Wiems Revolution Pro; 85 Hz bipolar, 350 μs, 4 s on/4 s off, 20 min sessions) three times per week (ten sessions). Safety was monitored with serial creatine kinase (CK), high-sensitivity troponin I (hs-TnI), N-terminal pro-brain natriuretic peptide (NT-proBNP), C-reactive protein (CRP), and venous blood gas with lactate, measured before and 2–3 h after each session. Outcomes: A modest, age-appropriate improvement in functional capacity was accompanied by substantial reverse left-ventricular remodelling: LVEF improved from 27% to 54% (Simpson biplane); peak workload from 66 to 97 W (+47%); six-minute walk test distance from 390 to 590 m (+51%); peak oxygen uptake from 17.42 to 19.02 mL/min/kg (+9.2%); and EQ-5D-5L visual analogue scale from 60 to 90/100. Pre-exercise NT-proBNP fluctuated across the ten sessions (range 318.3–1,019.3 pg/mL); the final-day rise to 1,019.3 pg/mL likely reflected greater training effort on the last exercise day, supported by the concurrently highest post-session venous lactate of the programme (4.4 mmol/L; Δ + 2.9 mmol/L). One-month International Physical Activity Questionnaire data demonstrated sustained increases in daily physical activity. CK, hs-TnI, CRP, and venous lactate remained within acceptable safety limits, with no clinical adverse events attributable to WB-EMS. Discussion: To our knowledge, this is the first report of WB-EMS combined with standard CR in an HFrEF patient. Comprehensive serial biomarker monitoring confirmed a favorable safety profile. Improvements across functional, echocardiographic, and quality-of-life domains are promising but require confirmation in randomized trials, as multiple concurrent therapeutic interventions preclude causal attribution to WB-EMS alone.

21 April 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
Damian SendrowskiDamian Sendrowski
Damian Sendrowski
APAgata Polańska-Szczap
Agata Polańska-Szczap
BHBeata Hus-Budziszewska
Beata Hus-Budziszewska
AVAnastasiia Vlaieva
Anastasiia Vlaieva
SMSzymon Markowski
Szymon Markowski
DKDariusz Kozłowski
Dariusz Kozłowski
Background: Peripheral muscle electrostimulation (PME), including neuromuscular electrical stimulation (NMES) and functional electrical stimulation (FES), has been increasingly acknowledged as an effective adjunctive or complementary treatment to voluntary exercise in elderly cardiac patients who cannot perform sufficient amounts of voluntary exercise, with limited research on optimal protocols. Sarcopenia, defined as a progressive decrease in muscle mass, strength and function, affects approximately 34% of heart failure (HF) patients and considerably worsens their prognosis. The objective of this systematic review is to summarize the current evidence on the theoretical mechanisms, physiological pathways, safety and efficacy of PME in older adults within a cardiac rehabilitation (CR) setting with a specific emphasis towards sarcopenia reversal. Methods: We performed a systematic review following PRISMA 2020 guidelines. A systematic search of the PubMed, Embase, Cochrane Library, CINAHL and PEDro databases from inception until December 2025 was conducted. We searched for randomized controlled trials (RCTs) and controlled clinical trials focusing on PME in patients with cardiac diseases aged 65 years or older. The main outcomes were physical function (assessed with the Short Physical Performance Battery [SPPB] and 6-minute walk distance [6MWD]), muscle strength, muscle mass, and safety. The Cochrane Risk of Bias tool was used for quality evaluation of the studies. Results: Eight studies were included, with 387 participants and mean age between 78 to 85 years. PME consistently improved lower extremity muscle strength (MD: 5.2% body weight, 95% CI = 1.2–9.1, p = 0.013) along with SPPB scores ranging from +2.3 to +2.67 points (all p < 0.05). Home-based NMES achieved 100% adherence rates and no cardiovascular adverse events were reported. The mechanisms by which PME is beneficial involve peripheral skeletal muscle adaptations without eliciting central hemodynamic stress, increased endothelial function, aerobic enzyme activity, protein anabolism stimulation and muscle proteolysis inhibition. No significant effects were observed on BNP levels, hospital readmissions or mortality. PME has been shown to attenuate the progression of sarcopenia through hypertrophy of type I and II muscle fibers, as well as mitochondrial biogenesis. Conclusions: PME is a safe, feasible adjunct to conventional CR in frail elderly cardiac patients, particularly those with exercise intolerance and sarcopenia. It improves peripheral muscle function, physical performance, and muscle protein balance without cardiovascular stress. Larger multicenter trials are needed to establish optimal protocols and long-term clinical outcomes. Registration: PROSPERO CRD420261347748 (protocol registered prior to data extraction).


15 May 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
Damian SendrowskiDamian Sendrowski
Damian Sendrowski
MSMartyna Kaja Sendrowska
Martyna Kaja Sendrowska
DKDariusz Kozlowski
Dariusz Kozlowski
This article presents a longue durée synthesis of rehabilitative practices directed at older adults from antiquity to the early twenty-first century. Drawing on medical treatises, monastic and charitable statutes, hospital and insurance records, welfare legislation and contemporary policy frameworks, the article asks three questions: how societies have constructed ‘old age’ in ways that govern eligibility for rehabilitative intervention; which institutions and actors have delivered such care, and under what economic and political conditions; and how the experiences and agency of older patients have shaped, and been shaped by, rehabilitative regimes. The narrative proceeds through eight comparative case-study sections covering Greco-Roman antiquity, Ancient Egypt, classical Indian and Chinese medicine, the Islamic bimaristan tradition, pre-Columbian American civilisations, indigenous African and Australasian healing systems, medieval and early modern Europe, the long nineteenth century, the rise of twentieth-century geriatrics and the emergence of contemporary delivery models (inpatient comprehensive geriatric assessment, early supported discharge, day-hospital care, restorative nursing-home programmes, reablement and telerehabilitation). The article argues that rehabilitation for the elderly has always been bound up with shifting configurations of welfare, work and citizenship, and that the question of who is considered worthy of rehabilitative investment has been a political one, however thoroughly disguised in clinical language. It concludes by situating the recent UN Human Rights Council resolution of 3 April 2025 within a longer history of contested entitlement and by identifying ageism, fragmented financing and workforce shortages as the principal structural barriers to a rights-based rehabilitation framework for older adults today.

29 July 2026 in Monash Bioethics Review
Verified
Journal Article
Open access
PDF file
Damian SendrowskiDamian Sendrowski
Damian Sendrowski
DKDariusz Kozlowski
Dariusz Kozlowski
Clinicians have long used the phrase the hidden patient to describe the relative who cares for a declining elder and whose own health quietly fails in the process. The moral philosophy of ageing has not taken the phrase seriously. It has concentrated on the older person, on her autonomy and her dignity, and has left the family that sustains her at the margin of attention. This paper argues that the phrase is more than a clinical courtesy. When serious illness and frailty arrive in later life they characteristically produce a second patient, the carer, whose suffering is real, measurable, gendered and, for the most part, unrecognised. We defend the claim on two grounds that the existing literature has kept apart. First, we extend the phenomenology of illness from the patient to the carer, showing that the contraction of the lifeworld that phenomenologists describe in the ill person recurs, in a related form, in the person who tends her. Second, we identify a moral hazard internal to care itself, by which the responsiveness that makes family care valuable is also what exposes the carer to exploitation, so that her love is enlisted as a substitute for social provision. We trace the invisibility of this second patient to the model of the independent self that governs modern moral thought, and we draw out what follows for clinical practice and for justice. The carer is owed the standing of a co-patient, not the gratitude reserved for a volunteer. Graphical abstract